[Iatrogenic damage possibilities in the drug therapy of neurologic and psychiatric diseases].
D000547:Amantadine / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D001463:Barbiturates / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D002220:Carbamazepine / Q000009:adverse effects; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D055598:Chemical Phenomena; D002621:Chemistry; D003276:Contraceptives, Oral; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects; D001523:Mental Disorders / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000188:drug therapy*; D010276:Parasympatholytics / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy; D011247:Pregnancy; D013388:Succinimides / Q000009:adverse effects
D000927:Anticonvulsants; D001463:Barbiturates; D003276:Contraceptives, Oral; D006827:Hydantoins; D010276:Parasympatholytics; D013388:Succinimides; D001569:Benzodiazepines; D002220:Carbamazepine; D004295:Dihydroxyphenylalanine; D000547:Amantadine
Iatrogene Schädigungsmöglichkeiten bei der medikamentösen Therapie neurologischer und psychiatrischer Erkrankungen.